219 related articles for article (PubMed ID: 14630810)
1. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.
Coughlin CM; Vance BA; Grupp SA; Vonderheide RH
Blood; 2004 Mar; 103(6):2046-54. PubMed ID: 14630810
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
[TBL] [Abstract][Full Text] [Related]
3. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
4. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
5. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.
Kim SK; Nguyen Pham TN; Nguyen Hoang TM; Kang HK; Jin CJ; Nam JH; Chung SY; Choi SJ; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
Ann Hematol; 2009 Nov; 88(11):1113-23. PubMed ID: 19277657
[TBL] [Abstract][Full Text] [Related]
6. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
7. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
8. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
[TBL] [Abstract][Full Text] [Related]
9. CD40-activated B cells induce anti-tumor immunity in vivo.
Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
[TBL] [Abstract][Full Text] [Related]
10. A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA.
Wan Y; Ma X; Li X; Yi J
Med Hypotheses; 2009 Nov; 73(5):835-7. PubMed ID: 19632790
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
12. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
[TBL] [Abstract][Full Text] [Related]
13. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
[TBL] [Abstract][Full Text] [Related]
14. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
Schultze JL; Anderson KC; Gilleece MH; Gribben JG; Nadler LM
Br J Haematol; 2001 May; 113(2):455-60. PubMed ID: 11380416
[TBL] [Abstract][Full Text] [Related]
16. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
17. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
[TBL] [Abstract][Full Text] [Related]
18. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
19. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.
Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
